Logo

American Heart Association

  18
  0


Final ID: MP911

Risk Stratification Model on Mortality in Vulnerable Patients with Chronic Limb-Threatening Ischemia

Abstract Body (Do not enter title and authors here): Background: The prevalence of peripheral arterial disease, including chronic limb-threatening ischemia (CLTI), is globally increasing due to the aging society and the pandemics of diabetes mellitus. Although managing elderly CLTI patients with non-ambulatory status is substantially common in clinical practice, determination of treatment planning remains clinically challenging. This study aimed to evaluate the mortality and prognostic factors in elderly CLTI patients with non-ambulatory.
Methods: This was a multicenter retrospective observational study enrolling 2309 CLTI patients (age: 75.5 ± 10.2 years, male: 60.5%, diabetes mellitus: 61.9%, dialysis: 46.9%) who underwent endovascular therapy (EVT) between April 2010 and March 2024. Patients aged over 80 years old with non-ambulatory status including wheelchair or bedridden were defined as the vulnerable CLTI group. The primary outcome measure was all-cause mortality, and were analyzed by multivariate analysis.
Results: A total of 443 patients (19.2%) were classified as vulnerable CLTI. The 5-year all-cause mortality rate was 76.4% in the vulnerable CLTI group and 49.9% in the non-vulnerable CLTI group (p<0.001). The multivariate analysis revealed hemodialysis (hazard ratio [HR]: 1.83, p < 0.001), wound, ischemia, and foot infection (WIfI) stage 4 (HR: 1.71, p = 0.002), left ventricular ejection fraction < 50% (HR: 1.52, p = 0.04), and serum albumin level < 3 g/dL (HR: 1.55, p = 0.009) were positively associated with mortality in vulnerable CLTI group, with no significant interactions. 12-month mortality rate was 71.6% in patients with three or more of these risk factors.
Conclusions: The current study revealed that hemodialysis, wound severity, malnutrition, and cardiac dysfunction were significantly associated with mortality in vulnerable CLTI patients. Risk stratification based on these predictors allows estimation of prognosis in vulnerable CLTI patients, and would be clinically useful for determination of treatment planning including palliative care.
  • Yoshii, Daichi  ( Osaka Keisatsu Hospital , Osaka , Japan )
  • Higuchi, Yoshiharu  ( Osaka Keisatsu Hospital , Osaka , Japan )
  • Iida, Osamu  ( Osaka Keisatsu Hospital , Osaka , Japan )
  • Sotomi, Yohei  ( Osaka University , Osaka , Japan )
  • Sakata, Yasushi  ( Osaka University , Osaka , Japan )
  • Hata, Yosuke  ( Kansai Rosai Hospital , Amagasaki , Japan )
  • Toyoshima, Taku  ( Osaka Keisatsu Hospital , Osaka , Japan )
  • Okina, Yoshiteru  ( Osaka Keisatsu Hospital , Osaka , Japan )
  • Nakao, Sho  ( Kansai Rosai Hospital , Amagasaki , Japan )
  • Yamane, Haruya  ( NHO Osaka National Hospital , Osaka , Japan )
  • Ukai, Kazuho  ( NHO Osaka National Hospital , Osaka , Japan )
  • Ikeoka, Kuniyasu  ( NHO Osaka National Hospital , Osaka , Japan )
  • Nohara, Hiroaki  ( Osaka Rosai Hospital , Osaka , Japan )
  • Author Disclosures:
    Daichi Yoshii: DO NOT have relevant financial relationships | Yoshiharu Higuchi: No Answer | Osamu Iida: No Answer | Yohei Sotomi: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott Medical Japan:Active (exists now) ; Speaker:Boehringer Ingelheim:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Speaker:Bristole-Myers Squibb:Active (exists now) | Yasushi Sakata: DO have relevant financial relationships ; Speaker:Novo Nordics:Active (exists now) ; Speaker:Ono Pharamaceutical:Active (exists now) ; Speaker:Janssen Pharmacheutical:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Speaker:Novartis Pharma:Active (exists now) ; Speaker:Nippon Boehringer Ingelheim:Active (exists now) ; Speaker:Otsuka Pharmaceutical:Past (completed) ; Speaker:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):BIOTRONIK JAPAN:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific Japan:Active (exists now) ; Research Funding (PI or named investigator):Otsuka Pharmaceutical:Active (exists now) ; Research Funding (PI or named investigator):Abbot Japan:Active (exists now) | Yosuke Hata: DO NOT have relevant financial relationships | Taku Toyoshima: No Answer | Yoshiteru Okina: DO NOT have relevant financial relationships | Sho Nakao: No Answer | Haruya Yamane: DO NOT have relevant financial relationships | Kazuho Ukai: DO NOT have relevant financial relationships | Kuniyasu Ikeoka: DO NOT have relevant financial relationships | Hiroaki Nohara: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Medical Therapy in Peripheral Artery Disease

Saturday, 11/08/2025 , 12:15PM - 01:25PM

Moderated Digital Poster Session

More abstracts on this topic:
Association of pre-thrombectomy infarct topography and hemorrhagic transformation in patients with acute ischemic stroke: A multicenter Bayesian analysis

Bonkhoff Anna, Simonsen Claus, Patel Aman, Rost Natalia, Regenhardt Robert, Schirmer Markus, Favilla Christopher, Das Alvin, Dmytriw Adam, Gupta Rajiv, Rabinov James, Stapleton Christopher, Leslie-mazwi Thabele

Comparing Combined Pneumococcal and Influenza Vaccines to Influenza Vaccine Alone in Coronary Artery Disease Patients: A Propensity Matched Analysis

Jaiswal Vikash, Hanif Muhammad, Jaiswal Akash, Sundas Fnu, Danisha Fnu, Deb Novonil, Bytyci Ibadete

More abstracts from these authors:
Prolonged Procedure Time and Its Association with Peri-Procedural Complications in Endovascular Therapy for Symptomatic Lower Extremity Arterial Disease

Toyoshima Taku, Iida Osamu, Higuchi Yoshiharu

Win Ratio Analysis of Low-Voltage Area Ablation in Persistent Atrial Fibrillation: a Sub-Analysis of the SUPPRESS-AF Study

Sunaga Akihiro, Tanaka Nobuaki, Watanabe Tetsuya, Inoue Koichi, Sotomi Yohei, Sakata Yasushi, Matsuoka Yuki, Nakatani Daisaku, Okada Katsuki, Kida Hirota, Sakamoto Daisuke, Hasegawa Hideaki, Kitamura Tetsuhisa, Masuda Masaharu

You have to be authorized to contact abstract author. Please, Login
Not Available